What BioNTech’s CureVac Deal Says About mRNA’s Future

BioNTech’s $1.25B CureVac deal pushes mRNA beyond vaccines toward cancer treatment

10 Nov 2025

BioNTech has agreed to acquire German biotech rival CureVac in an all-stock deal valued at $1.25bn, marking a significant step in the expansion of messenger RNA (mRNA) technology beyond its pandemic-era use in vaccines. The transaction, announced on June 12 and expected to close later this year, will combine two early pioneers of mRNA research that once competed directly in the same field.

BioNTech, which developed a leading COVID-19 vaccine in partnership with Pfizer, said the acquisition would reinforce its strategy to apply mRNA to cancer treatment. “This acquisition is another building block in BioNTech’s oncology strategy and an investment in the future of cancer medicine,” said chief executive Uğur Şahin.

The deal gives BioNTech access to CureVac’s mRNA manufacturing facilities, patent portfolio, and expertise in molecule stabilization, key assets as the company seeks to build a full-scale oncology platform. CureVac’s technology, developed over more than two decades, focuses on refining mRNA for improved stability and precision, which could enhance the design of personalized cancer therapies.

The move highlights a broader industry shift as biotech groups move away from mass-market infectious disease vaccines and toward higher-value treatments for cancer and rare genetic disorders. By integrating CureVac’s production and research operations, BioNTech aims to strengthen control over its entire development chain, from discovery through global distribution.

Challenges remain. Most mRNA cancer therapies are still in early-stage clinical trials, with uncertain timelines and outcomes. CureVac’s earlier difficulties in developing an effective COVID-19 vaccine underscore the risks involved in adapting mRNA for complex diseases such as cancer.

Nevertheless, advances in delivery systems and manufacturing efficiency are raising expectations for faster progress in therapeutic mRNA. If successful, BioNTech’s acquisition could accelerate not only its own diversification beyond infectious diseases but also the broader adoption of mRNA as a platform for precision medicine.